Skip to main content
main-content

05-08-2022 | JAK inhibitors | Video

Have the ORAL Surveillance results changed rheumatology practice?

share
SHARE

Following publication of the ORAL Surveillance trial, Richard Conway and Kevin Winthrop discuss the impact of the findings on JAK inhibitor prescribing, how regulatory recommendations compare in Europe and the USA, and whether the risks seen with tofacitinib represent a class effect.

Related content

11-08-2021 | JAK inhibitors | Feature | Article

JAK inhibitor safety: Distilling the evidence

Peter Nash discusses the latest evidence on the association between JAK inhibitors and the risk for VTE, MACE, and malignancy